GlassScriptPhysician profile
Chad A Thomas
NPI 1528030863
$4,356.99
in general payments reported to CMS, 2019-2025
26 companies · $795 in 2025
The $795 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,270 · 2022: $812 · 2023: $741 · 2024: $740 · 2025: $795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258 · Education: $17.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,257.90 |
| Education | $17.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,767.38 | 2021-2025 | |
| Gilead Sciences, INC. | $474.31 | 2021-2025 | |
| Pfizer INC. | $368.51 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $322.91 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.26 | 2021-2024 | Xifaxan |
| Braintree Laboratories, INC. | $148.86 | 2021-2023 | Sutab |
| Genzyme Corporation | $146.72 | 2023-2025 | |
| Janssen Biotech, INC. | $119.59 | 2024-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $92.82 | 2022-2025 | Dupixent |
| Redhill Biopharma INC. | $71.64 | 2021 | |
| Ironwood Pharmaceuticals, INC | $63.49 | 2021-2023 | Linzess |
| Celgene Corporation | $59.27 | 2023-2024 | Zeposia |
| Celltrion USA INC. | $49.13 | 2024-2025 | Vegzelma, Zymfentra |
| Daiichi Sankyo INC. | $48.60 | 2024-2025 | Injectafer |
| Axonics, INC. | $45.88 | 2022-2024 | Axonics |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $45.66 | 2023 | Sucraid |
| Merck Sharp & Dohme LLC | $44.06 | 2021 | |
| Intercept Pharmaceuticals, INC. | $35.55 | 2025 | |
| Ardelyx, INC. | $31.08 | 2023 | Ibsrela |
| Madrigal Pharmaceuticals | $29.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $25.72 | 2021 | |
| Phathom Pharmaceuticals, INC. | $24.93 | 2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $22.49 | 2022 | |
| Novo Nordisk INC | $21.18 | 2025 | Wegovy |
| Alfasigma USA, INC. | $20.27 | 2021 | |
| Sandoz INC. | $16.04 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.